CareDx Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:N/A
Lead Investor(s):Craig-Hallum Capital Group

Industry Ranking

Estimated Revenue & Financials

  • CareDx's estimated annual revenue is currently $76.6M per year.
  • CareDx received $18.3M in venture funding in October 2017.
  • CareDx's estimated revenue per employee is $199,398

Employee Data

  • CareDx has 384 Employees.
  • CareDx grew their employee count by 34% last year.
  • CareDx currently has 55 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Missing a competitor? Contribute!?

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSureĀ® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. About AlloMapĀ® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.

keywords:Healthcare,Medical Diagnostics


Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







CareDx News

09/03/2019 - CareDx Acquires XynManagement For Pre-Transplant Tech

CareDx has announced a deal to acquire XynManagement for an undisclosed sum. XynManagement has developed a suite of software tools to ...

09/08/2019 - CareDx Acquires XynManagement

28, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and ...

09/03/2019 - Allianz Asset Management GmbH Has $4.37 Million Position in CareDx Inc (NASDAQ:CDNA)

Allianz Asset Management GmbH reduced its stake in CareDx Inc (NASDAQ:CDNA) by 14.5% during the 2nd quarter, according to the ...

CareDx Funding

DateAmountRoundLead InvestorsReference
2015-02-04$20.0MUndisclosedEast West BankArticle
2016-09-22$UndisclosedUndisclosedPiper Jaffray & CoArticle
2017-10-12$18.3MUndisclosedCraig-Hallum Capital GroupArticle

CareDx Executive Hires

2015-01-06John J. SninskyChief Scientific OfficerArticle
2016-03-25Charles ConstantiCFOArticle
2017-04-25Michael BellCFOArticle